Switch theme
Sign up to access all valuation multiples
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
2018
11
LTM Revenue n/a
LTM EBITDA n/a
-$94.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Climb Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Climb Bio achieved revenue of n/a and an EBITDA of -$40.3M.
Climb Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Climb Bio valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$45.1M | -$40.3M | n/a | n/a | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | NaN% | NaN% | XXX |
| Net Profit | -$47.5M | -$45.2M | -$35.1M | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | -Infinity% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Climb Bio's stock price is $1.
Climb Bio has current market cap of $98.9M, and EV of -$94.4M.
See Climb Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$94.4M | $98.9M | XXX | XXX | XXX | XXX | $-1.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Climb Bio has market cap of $98.9M and EV of -$94.4M.
Climb Bio's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Climb Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Climb Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$94.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpClimb Bio's NTM/LTM revenue growth is n/a
Climb Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.7M for the same period.
Over next 12 months, Climb Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Climb Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Climb Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Climb Bio acquired XXX companies to date.
Last acquisition by Climb Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Climb Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Climb Bio founded? | Climb Bio was founded in 2018. |
| Where is Climb Bio headquartered? | Climb Bio is headquartered in United States of America. |
| How many employees does Climb Bio have? | As of today, Climb Bio has 11 employees. |
| Who is the CEO of Climb Bio? | Climb Bio's CEO is Dr. Aoife M. Brennan, M.B.. |
| Is Climb Bio publicy listed? | Yes, Climb Bio is a public company listed on NAS. |
| What is the stock symbol of Climb Bio? | Climb Bio trades under CLYM ticker. |
| When did Climb Bio go public? | Climb Bio went public in 2021. |
| Who are competitors of Climb Bio? | Similar companies to Climb Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Climb Bio? | Climb Bio's current market cap is $98.9M |
| Is Climb Bio profitable? | Yes, Climb Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
